News Hub | News Direct

Defense Acquisition University (DAU) to Support NCMA Nexus 2024

National Contract Management Association

The National Contract Management Association (NCMA) is pleased to announce the collaboration with the Defense Acquisition University (DAU) for the inaugural Nexus 2024 conference, scheduled from March 3-6 in Jacksonville, FL. This strategic partnership is a significant milestone for NCMA as it reinforces the commitment to advancing the knowledge and skills of the defense acquisition workforce. Notably, participants in Nexus 2024 will benefit from transferable credits toward their certifications, making this collaboration with DAU particularly valuable for professionals seeking career development opportunities. Nexus 2024, offers a unique platform for cross-functional collaboration for both government and industry to address pressing issues in federal procurement, including supply chain risk, cybersecurity, and sustainability. The event encourages joint efforts in innovation, strategic discussions, case studies, hackathons, and real-world problem-solving, providing deployable solutions for attendees. The co-hosted event aligns seamlessly with the new Better Contracting Initiative (BCI), emphasizing that multi-functional groups come together to learn the acquisition lifecycle side by side, promoting a comprehensive understanding of each’s others perspective job functions along with federal procurement challenges. One of the emcees for Nexus 2024 is DAU’s Professor of Program Management, Julie Knechtel, expressed her excitement about the event, stating, "I am excited to be part of an event that brings together diverse perspectives and expertise in defense acquisition. It is a great opportunity to train as we work, leverage the expertise of multi-functional teams, and enhance the skills needed to tackle the evolving challenges in federal procurement collaboratively." NCMA's Chief Executive Officer, Kraig Conrad, commented on the natural fit between NCMA and DAU, saying, "The collaboration with DAU at Nexus 2024 exemplifies our shared commitment to advancing the knowledge and skills of the acquisition workforce. We are grateful for their support as together we drive better practices and better outcomes in acquisition and procurement.” Michelle Currier, NCMA's Chief Learning Officer, also shared her enthusiasm, stating, "The Nexus 2024 event underscores the importance of collaboration and continuous learning in federal procurement. DAU's support enhances the educational value of the event, aligning with the goals of not only NCMA, but the federal government overall." Nexus 2024 is open to all professionals involved in federal procurement, providing an ideal opportunity for integrated teams to learn and train together. For more information about Nexus 2024 and to register for the event, visit the NCMA website at http://www.ncmahq.org/nexus. The National Contract Management Association (NCMA) – www.ncmahq.org – stands as the premier contract management organization whose mission is to collaborate towards a globally recognized contract management profession that strengthens its nexus with related acquisition communities. Serving approximately 20,000 members in both the public and private sectors, NCMA propels the growth, advancement, and impact of practitioners through a steadfast commitment to serve through the open exchange of ideas in neutral forums. DAU is the acquisition learning, development and talent management organization for the Department of Defense with a mission to provide a global learning environment to develop qualified acquisition, requirements, and contingency professionals who deliver and sustain effective and affordable warfighting capabilities. Nearly 160,000 acquisition professionals across all military services and Department of Defense agencies have access to career-long learning and support from DAU faculty and staff. Contact Details Holly DeHesa +1 281-865-3296 dominick.belfiore@ncmahq.org Company Website https://www.ncmahq.org

January 11, 2024 05:05 AM Eastern Standard Time

UNOS Hires New Vice President of External Affairs

United Network for Organ Sharing

The United Network for Organ Sharing (UNOS) has hired Alicia Hennie as its new vice president for external affairs. As the leader of the external affairs team, Hennie advocates for impactful policies and legislation on behalf of transplant patients with the mission of saving as many lives as possible. She’s responsible for strengthening and growing relationships with federal and state government and regulatory officials, as well as patient groups and industry groups. Hennie joins UNOS with more than two decades of public policy and advocacy experience. She previously served as a presidential appointee at the U.S. Department of Health and Human Services and has worked for the Senate Aging Committee and the Senate HELP Committee. More recently, she held senior government affairs roles at PhRMA and Varian, a Siemens Healthineers Company. “Alicia has been advocating for patients for nearly 20 years and will be a great champion for our nation’s transplant patients and organ donors,” said UNOS Chief of Staff Julie Nolan, who previously held the vice president of external affairs role. “I’m confident her experience and relationships will drive meaningful changes that will strengthen the organ donation and transplant system, helping more patients get the lifesaving transplants they need.” Hennie is based in Washington, D.C. She has a bachelor’s degree in history from Wheaton College. About UNOS United Network for Organ Sharing (UNOS) is the mission-driven non-profit serving as the nation’s transplant system under contract with the federal government. We lead the network of transplant hospitals, organ procurement organizations, and thousands of volunteers who are dedicated to honoring the gifts of life entrusted to us and to making lifesaving transplants possible for patients in need. Working together, we leverage data and advances in science and technology to continuously strengthen the system, increase the number of organs recovered and the number of transplants performed, and ensure patients across the nation have equitable access to transplant. Contact Details United Network for Organ Sharing Anne Paschke +1 804-782-4730 anne.paschke@unos.org Company Website https://unos.org

January 10, 2024 04:14 PM Eastern Standard Time

Image

G Medical Innovations Announces First Half 2023 Financial Results and Provides Business Update

G Medical Innovations Holdings Ltd

G Medical Innovations Holdings Ltd. (Nasdaq: GMVDF) (“G Medical” or the “Company”), an early commercial stage healthcare company engaged in the development of next-generation mHealth and telemedicine solutions and monitoring service platforms, today announced its financial results and provided a business update for the six months ended June 30, 2023. First Half 2023 Financial Results The Company reported total revenues for the six-month period ended June 30, 2023 in the amount of approximately $3.1 million, compared with approximately $1.9 million for the six months ended June 30, 2022 Cash and cash equivalents as of June 30, 2023, were $2,009 thousand, compared to $295 thousand as of December 31, 2022. The increase compared to December 31, 2022, mainly reflects less cash used in operating activities and lower investments in fixed assets during the six months ended June 30, 2022. Research and development expenses for the six months ended June 30, 2023, were $972 thousand, representing a decrease of $217 thousand compared to $1,189 thousand in the six months ended June 30, 2022. The decrease is related to the products segment and is mainly related to the decrease of salaries and related expenses as well as in subcontractors. Selling, general, and administrative expenses for the six months ended June 30, 2023, were $8,202 thousand, representing a decrease of $3,889 thousand compared to $12,091 thousand in the six months ended June 30, 2022. The decrease is related mainly to a decrease in share-based compensation expenses in the amount of $1,327 thousand and to a decrease in share issuance costs of 1,545 thousand. Net loss for the six months ended June 30, 2023, was $6,083 thousand, or $1.13 per share attributed to shareholders of the Company, compared to $ 13,287 thousand or after giving effect to the reverse stock split in 2022, $ 25.31 per share attributed to shareholders of the Company, in the six months ended June 30, 2022. The decrease in net loss was mainly attributed to the Company's COVID-19 business activities. Net cash used in operating activities during the six months ended June 30, 2023, was $7,254 thousand, compared to $16,424 thousand during the six months ended June 30, 2022. The decrease consists primarily of net loss and revaluation of liability in respect of derivative liabilities. “The Company expects growth in its patient monitoring business”, said Dr. Yacov Geva, Chief Executive Officer of G Medical. The complete report is available on the company’s website, https://gmedinnovations.com/investors About G Medical Innovations Holdings Ltd. G Medical Innovations Holdings Ltd. is an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms. The Company’s solutions and services can empower consumers, patients, and providers to better monitor, manage and improve clinical and personal health outcomes, especially for those who suffer from cardiovascular disease, pulmonary disease and diabetes. The Company’s current product lines consist of its Prizma medical device, a clinical grade device that can transform almost any smartphone into a medical monitoring device enabling both healthcare providers and individuals to monitor, manage and share a wide range of vital signs and biometric indicators; its Extended Holter Patch System, a multi-channel patient-worn biosensor that captures electrocardiography data continuously, including its QT Syndrome Prolongation Detection Capabilities Patch; and 31 different at-home health tests kits. In addition, the Company is developing its Wireless Vital Signs Monitoring System, which is expected to provide full, continuous, and real-time monitoring of a wide range of vital signs and biometrics. Its monitoring services include provision of Independent Diagnostic Testing Facility monitoring services and private monitoring services. Visit https://gmedinnovations.com/. Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “should,” “could,” “seek,” “intend,” “plan,” “goal,” “estimate,” “anticipate” or other comparable terms. For example, the Company is using forward-looking statements when it discusses its future financial performance. All statements other than statements of historical facts included in this press release regarding the Company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on the Company’s current beliefs, expectations, and assumptions regarding the future of its business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control. The Company’s actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause the Company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: the Company’s ability to maintain access to sources of liquidity; the Company’s ability to successfully market its products and services; the Company’s expectation regarding government and third-party payors providing adequate coverage and reimbursement for the use of its products and services, including the Company’s COVID-19 and other related testing services; the acceptance of its products and services by customers; the Company’s continued ability to pay operating costs and ability to meet demand for its products and services; the amount and nature of competition from other medical device and at-home test kit businesses; the Company’s ability to successfully develop new products and services; the Company’s success establishing and maintaining collaborative, strategic alliance agreements, licensing and supplier arrangements; the Company’s ability to comply with applicable regulations; and the other risks and uncertainties described in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2022 filed with the Securities and Exchange Commission (the “SEC”) on May 16, 2023, and in any subsequent filings with the SEC. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Investor Relations Contact G Medical Innovations Holdings Ltd. +972 8-958-4777 service@gmedinnovations.com Dr. Yacov Geva G Medical Innovations Holdings Ltd. is an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms. The Company’s solutions and services can empower consumers, patients, and providers to better monitor, manage and improve clinical and personal health outcomes, especially for those who suffer from cardiovascular disease, pulmonary disease and diabetes. The Company’s current product lines consist of its Prizma medical device, a clinical grade device that can transform almost any smartphone into a medical monitoring device enabling both healthcare providers and individuals to monitor, manage and share a wide range of vital signs and biometric indicators; its Extended Holter Patch System, a multi-channel patient-worn biosensor that captures electrocardiography data continuously, including its QT Syndrome Prolongation Detection Capabilities Patch; and 31 different at-home health tests kits. In addition, the Company is developing its Wireless Vital Signs Monitoring System, which is expected to provide full, continuous, and real-time monitoring of a wide range of vital signs and biometrics. Its monitoring services include provision of Independent Diagnostic Testing Facility monitoring services and private monitoring services. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “should,” “could,” “seek,” “intend,” “plan,” “goal,” “estimate,” “anticipate” or other comparable terms. For example, the Company is using forward-looking statements when it discusses its future financial performance. All statements other than statements of historical facts included in this press release regarding the Company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on the Company’s current beliefs, expectations, and assumptions regarding the future of its business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control. The Company’s actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause the Company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: the Company’s ability to maintain access to sources of liquidity; the Company’s ability to successfully market its products and services; the Company’s expectation regarding government and third-party payors providing adequate coverage and reimbursement for the use of its products and services, including the Company’s COVID-19 and other related testing services; the acceptance of its products and services by customers; the Company’s continued ability to pay operating costs and ability to meet demand for its products and services; the amount and nature of competition from other medical device and at-home test kit businesses; the Company’s ability to successfully develop new products and services; the Company’s success establishing and maintaining collaborative, strategic alliance agreements, licensing and supplier arrangements; the Company’s ability to comply with applicable regulations; and the other risks and uncertainties described in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2022 filed with the Securities and Exchange Commission (the “SEC”) on May 16, 2023, and in any subsequent filings with the SEC. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Contact Details Rina Bar +972 54-724-0412 rinab@gmedinnovations.com Company Website https://gmedinnovations.com

January 10, 2024 03:01 PM Eastern Standard Time

Human-augmented AI data marketplace Ta-Da debuts on strategic MultiversX incubator xLaunchpad

STORM Partners

Ta-Da, the platform revolutionizing AI data annotation, announces its highly anticipated debut on xLaunchpad, MultiversX’s strategic incubator. This collaboration sets the stage for a groundbreaking advancement in the secure and ethical development of AI, harnessing the power of human-validated data. Founded on over seven years of expertise in AI, Ta-Da leverages the power of MultiversX blockchain technology to disrupt conventional data collection methods. With its focus on video, audio, and image verticals, Ta-Da introduces a hybrid model of data annotation that blends quality, cost-effectiveness, and scalability. Addressing major challenges in AI development, such as bias and high data-related costs, this approach has already proven its efficacy with over 2.5 million tasks completed during its public beta phase. “The future of AI is not just about algorithms but about the quality and diversity of data that trains these algorithms,” says William Simonin, CEO of Ta-Da. “ Our launch on xLaunchpad is a pivotal step in realizing our vision of creating more effective AI systems by harnessing the power of human insight and the robustness of blockchain technology. ” xLaunchpad is the strategic incubator and acceleration platform of the MultiversX blockchain ecosystem. It is renowned for backing the most ambitious and impactful technologies in the web3 space, enabling them to leverage MultiversX’s highly scalable and secure blockchain network, which processes over 30,000 transactions per second at negligible cost. “ Ta-Da’s innovative model for AI data annotation aligns perfectly with our mission to foster technological advancements that have a profound global impact, ” said Beniamin Mincu, CEO and founder of MultiversX. “ Their debut on xLaunchpad is a testament to our commitment to nurturing projects that tap into the massive opportunities that emerge from the convergence of blockchain and AI. ” The collaboration between Ta-Da and xLaunchpad signifies a transformative movement in AI and blockchain technology. It not only propels Ta-Da’s mission forward but also reinforces MultiversX’s position as a leader in supporting revolutionary tech initiatives. This partnership is set to redefine the landscape of AI development, making it more accessible, diverse, and efficient. The public launch event of Ta-Da on xLaunchpad is taking place on February 09, 2024. For more information and to be part of this transformative journey, visit https://xlaunchpad.com/tada About MultiversX MultiversX is a highly scalable, secure, and decentralized blockchain network built from first principles, to solve the two fundamental problems critical for widespread, global adoption: a transition from dialup to broadband, and a significant UX paradigm shift. Distributed by STORM Partners. Contact Adrian Bono for interviews and quotes -adrian.bono@storm.partners or telegram @STORMPartners Contact Details Dan Voicu +1 561-325-8757 dan.voicu@multiversx.com

January 10, 2024 09:12 AM Eastern Standard Time

Image

Beyond Diagnosis: Cardio Diagnostics' Actionable Clinical Intelligence Platform Provides Personalized Insights To Help Prevent Heart Attacks

Cardio Diagnostics Holdings, Inc

By Jeremy Golden, Benzinga An artificial intelligence-powered precision cardiovascular medicine company named Cardio Diagnostics (NASDAQ: CDIO) has launched a first-of-its-kind platform called Actionable Clinical Intelligence or ACI, that offers new epigenetic and genetic insights to clinicians prescribing the company’s Epi+Gen CHD and PrecisionCHD tests. Epi+Gen CHD is a powerful test that predicts the three-year risk for a coronary heart disease (CHD) event – a heart attack – and PrecisionCHD is a test for the detection of CHD. These AI-powered integrated genetic-epigenetic clinical tests only require a simple blood draw that can be performed at home or in provider settings without the need to wait weeks or months to get tested. Results from both of these laboratory-developed tests (LDTs) are coupled to the ACI platform. By merging LDT results with a patient’s unique epigenetic and genetic biomarkers and clinical information, ACI can provide deeper and actionable insights to clinicians about factors driving the patient’s CHD. Insights include the relative contribution of each of the patient’s biomarkers to CHD, evidence on the role of these biomarkers in CHD pathogenesis and changes in the measured biomarkers over time in response to lifestyle and therapeutic interventions. With the goal of improving patient outcomes, this evidence-based information is tailored to each patient to help elucidate areas of concern and aid a clinician’s independent assessments. “With ACI, we are expanding the tools available to healthcare providers, enabling them to make personalized, data-driven decisions that are informed by a patient's unique genetic and epigenetic profile,” said Tim Dogan, Ph.D., Chief Technology Officer of Cardio Diagnostics. “Empowering clinicians with insights, such as those offered by ACI, furthers our pursuit to help improve patient outcomes towards realizing a future where heart disease can be more effectively prevented, managed, and treated.” In addition to providing deeper insights to providers, ACI also has the potential to benefit employers and health plans. Health plans can leverage personalized insights from ACI to risk stratify and identify individuals in need of additional interventions. These heightened and targeted interventions may serve to reduce costly utilization and avoidable hospitalizations while helping improve chronic care management. This can reduce healthcare costs. For employers, adding the PrecisionCHD and Epi+Gen CHD tests with ACI into employee wellness programs can promote proactive management of factors contributing to CHD, which could improve overall employee health, reduce absenteeism and lower healthcare expenditures. Heart disease imposes significant costs on the U.S. healthcare system and workforce. According to the CDC, heart disease results in $147 billion per year in lost productivity. The condition leads to around 655,000 deaths annually – 1 in 4 of all deaths in the U.S. Given the widespread impact and high costs of heart disease, innovative solutions for prevention and early detection can provide significant value. For example, one study found that Cardio Diagnostics' Epi+Gen CHD test for assessing coronary heart disease risk could reduce costs by up to $42,000 per quality-adjusted life year compared to standard testing. With the ability to identify individuals at risk earlier and enable more personalized treatment plans, the company's epigenetic and genetic testing paired with the Actionable Clinical Intelligence platform aims to help mitigate the effects of heart disease – potentially saving lives and reducing strain on the healthcare system. Widespread adoption of such innovative approaches has the potential to significantly reduce the prevalence and consequences of heart disease nationwide. "Many at risk for or who already have coronary heart disease do not have traditional risk factors, signs, and symptoms,” said Meesha Dogan, Ph.D., CEO and Co-Founder at Cardio Diagnostics. “By harnessing the power of epigenetics, genetics, and AI, we now have the ability to personalize the management and treatment of heart disease at the molecular level, where biology happens. That is the promise of Precision Cardiovascular Medicine." Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. For more information, please visit www.cardiodiagnosticsinc.com. Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," “goal,” or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company’s ability to compete, regulatory matters, protection of technology, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Current Report on Form 10-K for the period ended December 31, 2022 and Form 10-Q for the period ended March 31, 2023, under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Gene Mannheimer - Investor Relations +1 855-226-9991 investors@cardiodiagnosticsinc.com Company Website https://cardiodiagnosticsinc.com/

January 09, 2024 09:00 AM Eastern Standard Time

5Scape VR Announces its Presale Going Live Today!

Spark Metro PR

In the thrilling realm of virtual reality (VR), 5th Scape stands as the gateway to the next big thing. Utilizing cutting-edge technology, 5th Scape promises a significant transformation in the online VR games platform niche, redefining the essence of immersive 3D gaming experiences. 5SCAPE Crypto Coins represent the first coins in the cryptocurrency world to offer exclusive access to premium VR content and devices, enhancing gaming experiences. Serving as a gateway to unlock special in-game features, these coins foster a dynamic community and present substantial growth potential within the virtual reality ecosystem. If you're interested in futuristic investment opportunities, cryptocurrency competes strongly with traditional avenues, and 5 Scape offers a rewarding future-proof investment. Click here to visit the 5 Scape Presale site Presale Countdown: 8 Hours Until Launch Prepare for an extraordinary journey into the limitless possibilities of virtual worlds! The 5th Scape team is thrilled to announce the presale launch happening TODAY in just 8 hours. This presale event introduces the 5SCAPE Coin, a token unlocking exclusive access to premium VR content, elevating gaming experiences to unparalleled heights. Get ready for an extraordinary journey into the limitless possibilities of virtual worlds! The 5th Scape team is thrilled to announce the upcoming presale launch, set to kick off in just 8 hours. This presale event introduces the 5SCAPE Coin, a token that will unlock exclusive access to premium VR content, elevating your gaming experiences to unparalleled heights. Presale Launch Details: Date: 09th January 2024 Time: 11 PM UTC +4 Total Funding Goal: $15 Million Click here to visit the 5 Scape Presale site 5SCAPE Coin - Your Key to Unmatched Virtual Reality Adventures At the center of the 5th Scape ecosystem, 5SCAPE coins are not just a currency but your ticket to a world where imagination meets innovation. As the presale events commence, game enthusiasts have the opportunity to be among the first to acquire 5SCAPE tokens, offering entry to exciting 3D VR games, powerful VR headsets with HDR quality, and ergonomically designed gaming chairs for utmost comfort during missions. Presale Highlights: The current price of 5Scape token at launch is $0.00187 Throughout all presale rounds, the 5scape token price is expected to appreciate by 400%, reaching a total value of $0.01. As the first VR ecosystem in the Ethereum crypto world, the 5th Scape project anticipates a reliable future without significant market competition. Early birds/Early enrollees will gain an exclusive advantage to access VR games and devices. Enjoy substantial discounts on all digital products with 5Scape tokens. Rest assured about data safety and confidentiality, protected by decentralized blockchain technology. Join Us in Redefining Reality 5th Scape is not just a project; it's a mission to reshape the virtual reality landscape. With a vision to be the forefront innovator in the VR industry, 5th Scape invites visionary investors, long-term investors, game developers, and gaming enthusiasts to join this thrilling and adventurous journey. Be part of the future of virtual reality gaming with 5scape. Don't Miss this fantastic opportunity to invest in 5th Scape, where technology and imagination converge to create a virtual world like never before. About 5th Scape: 5th Scape is a cutting-edge online VR games platform poised to redefine immersive gaming experiences. With the 5SCAPE Coin, 5th Scape offers exclusive access to premium VR content, animations, educational content, movies, and much more, creating a dynamic community within the virtual reality landscape. Follow 5thScape on social media for the latest updates: Twitter: @5th_scape Telegram: @fifthScape Discord: @5thscape Join the conversation using #5thScapeVR Contact Details Spark Metro Sumit Kumar +1 302-597-6768 sales@sparkmetro.com

January 09, 2024 04:53 AM Eastern Standard Time

Image

AmeriLife Names Gideon Moore Chief Legal Officer

AmeriLife

AmeriLife Group, LLC (“AmeriLife”), a national leader in developing, marketing, and distributing life and health insurance, annuities, and retirement planning solutions, announced today that Gideon Moore has been named Chief Legal Officer. Reporting to AmeriLife’s Chairman and Chief Executive Officer, Scott R. Perry, Moore will serve as the company’s lead legal counsel, managing AmeriLife’s Legal and Compliance department and advising its Board of Directors and Executive Leadership Team on all legal, regulatory, corporate governance, investment, transactional, and risk issues. Moore succeeds Nathan Hightower, who announced his retirement in late 2023 following a distinguished legal career and nearly 20 years with AmeriLife. “I’m excited to welcome Gideon back to the AmeriLife family,” said Perry. “Over the course of his career, Gideon has demonstrated both an exceptional legal mind and a passion for serving others. I look forward to working with him as a member of our Executive Leadership Team and confident in his abilities to lead our Legal and Compliance team.” “I’m excited to return to AmeriLife to lead a tremendous group of legal and compliance professionals,” added Moore. “I look forward to supporting AmeriLife’s growth and helping to create more opportunities to positively impact families and communities across the country.” Moore joins AmeriLife from Apex Service Partners in Tampa, Fla., where he served as General Counsel and Secretary since 2022. In this role, he established and scaled the company’s legal department through a period of rapid business expansion, providing cross-functional legal support and services for corporate development, real estate, employee relations, and procurement matters, among others. Prior to Apex, Moore served in progressively senior legal roles at AmeriLife for more than seven years, most recently as Associate General Counsel and Secretary overseeing all legal matters related to the company’s mergers and acquisitions efforts. During his time with AmeriLife, he was named a finalist for the Tampa Bay Business Journal’s 2016 Top Corporate Counsel award. Moore began his career with the historic white-shoe law firm, Cadwalader, Wickersham & Taft LLP, where he spent four years in its Corporate and Global Finance Departments. Moore, who will be based at AmeriLife’s Clearwater headquarters, received his J.D. from Duke University School of Law and B.A. from the University of North Carolina at Chapel Hill. ### About AmeriLife AmeriLife’s strength is its mission: to provide insurance and retirement solutions to help people live longer, healthier lives. In doing so, AmeriLife has become recognized as an industry leader in developing, marketing and distributing life and health insurance, annuities, and retirement planning solutions to enhance the lives of pre-retirees and retirees across the United States. For more than 50 years, AmeriLife has partnered with top insurance carriers to provide value and quality to customers served through a national distribution network of over 300,000 agents and financial professionals and more than 120 marketing organizations and insurance agencies. For more information, visit AmeriLife.com, and follow AmeriLife on Facebook and LinkedIn. Contact Details Media Jeff Maldonado +1 321-297-1112 jmaldonado@amerilife.com Partnership Inquiries Patrick Nichols +1 727-726-0726 pnichols@amerilife.com Company Website https://amerilife.com/

January 08, 2024 01:00 PM Eastern Standard Time

Newsletter - How G Medical Innovations is transforming telehealth and mobile cardiac telemetry in 2024

G Medical Innovations Holdings Ltd

A revolutionary chronic care management system that empowers patients to take control of their health A suite of sensors, such as 1-lead ECG, SPO2, temperature, BP, and weight scale, that can be used by the patients at home and transmit their vital signs and other measurements to the cloud in real-time. Portals and Smartphone Apps for the patients and physicians, where they can view trends and history, perform video conferences, write prescriptions and meeting summaries, and receive alerts for any abnormality or symptom detected. A secured HIPAA compliance cloud-based platform where the data from the sensors are stored, analyzed, and shared securely. We are thrilled to introduce our new flagship product, the Prizma, an ecosystem that empowers patients to take control of their health and enables physicians to monitor their patients and improve outcomes. Prizma consists of the following components: Prizma has many benefits for both patients and providers. For patients, it can improve their quality of life, reduce hospital visits, and lower their healthcare costs. For providers, it can enhance their efficiency, accuracy, and productivity. It can also empower patients to take control of their medical conditions. Prizma ecosystem allows physicians to offer their patients RPM and RPT services, which are covered by CPT codes and, on the one hand, improve patients' treatment and, on the other hand, allow the clinic to generate additional revenue streamline. We are proud of our innovation and believe that Prizma is a game changer in the healthcare industry and in the lives of our patients. Our expanded telehealth network and partnerships We are also excited to share with you that we have expanded our telehealth network and partnerships with leading healthcare providers and insurers across the country. We now offer our telehealth solutions and mobile cardiac telemetry services to more than 100 million members and patients, covering a wide range of cardiac conditions and needs. Our telehealth solutions and mobile cardiac telemetry services are designed to provide convenient, accessible, and affordable care to our customers and patients. Our telehealth solutions and mobile cardiac telemetry services are proven to improve outcomes, reduce costs, and enhance quality of life. Facts you may not be aware of The Triple Analysis you need to know about, how our service enhances your patient care in extra 2 unique steps. Did you know that at the end of each MCT study, the entire report undergoes a double screening to detect events that the device's algorithm did not detect in real-time? At G Medical, this is our unique approach: An AI-based algorithm conducts the first screen and is then verified by certified cardiac technicians. On average, 16% more events are identified during the end-of-study screening. We are committed to you and your patients, and we triple-check each case. The outcome justifies our efforts. Leading the 4 th healthcare revolution with our investment in R&D, quality assurance, and regulations We are committed to investing in research and development to bring you the most cutting-edge solutions for home hospitalization and remote treatment. These are the core values of the 4th healthcare revolution, which we are proud to be part of. Our R&D team is constantly working on enhancing our flagship product, the Prizma eco-system, as well as developing new sensors and monitoring solutions that are not available today. Prizma is a smart portable device that can monitor vital signs, detect abnormalities, and alert medical professionals in real-time. It can also sync with our cloud-based platform, where we can store, analyze, and share the data securely. We are excited to share our R&D efforts with you, and we look forward to launching these new features soon. As our customer, you will be the first to use them and enjoy the benefits of being part of the 4th healthcare revolution. Our culture and team spirit Finally, we want to acknowledge and celebrate our culture and team spirit that makes us who we are. We have fostered a collaborative, diverse, and inclusive work environment that values and respects each and every one of our team members. We have welcomed new talent and expertise to our team and provided opportunities for learning and development for our existing staff. Our team receives ongoing training and education from leading industry instructors, which keeps them up-to-date and enables them to provide you with our well-known high-service standards. In addition, our company culture reflects our commitment to delivering our well-known personal, attentive, and flexible service to our customers. We respect your preferences, adapt to your requirements, and ensure your satisfaction throughout the process. To conclude, We know that you have alternatives, and we are truly grateful and honored to have you as our valued customer and partner in this journey. We look forward to serving you and meeting your needs in the coming year and beyond. If you want to learn more about our telehealth solutions and mobile cardiac telemetry services, please visit our website at https://gmedinnovations.com/ or contact our sales team at support.us@gmedinnovations.com. You can also follow us on LinkedIn: https://www.linkedin.com/company/g-medical-innovations/ for more updates and news. Sincerely, Dr. Yacov Geva CEO and President of G Medical Innovations G Medical Innovations Holdings Ltd. is a health care company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms. The Company’s solutions and services can empower consumers, patients, and providers to better monitor, manage and improve clinical and personal health outcomes, especially for those who suffer from cardiovascular disease, pulmonary disease, and diabetes. The Company’s current product lines consist of its Prizma medical device, a clinical-grade device that can transform almost any smartphone into a medical monitoring device, enabling both health care providers and individuals to monitor, manage and share a wide range of vital signs and biometric indicators; its Extended Holter and Monitoring Cardiac Telemetry Patch services, utilizing multi-channel patient-worn biosensors with algorithms, to generate real time analysis and transmission that captures electrocardiography data continuously, including QT syndrome prolongation detection. In addition, the Company is developing its wireless vital signs monitoring system, which is expected to provide full, continuous, and real-time monitoring of a wide range of vital signs and biometrics. Its monitoring services include provision of independent diagnostic testing facility monitoring services and private monitoring services. This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, G Medical Innovations is using forward-looking statements when it discusses: revenue growth and profitability in future periods; the launch of the Company’s CLIA lab in Austin, TX, the Company’s online store for its Prizma Monitoring Devices on Amazon Marketplace and the Company’s HTKs business and online stores; potential announcements with large homecare service companies and large distributors for devices and At Home Test Kits; and the Company’s plans to expand its line of monitoring products and services offered to patients, hospitals and clinics. Because such statements deal with future events and are based on the Company’s current expectations, they are subject to various risks and uncertainties, and actual results, performance, or achievements of G Medical Innovations could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties,, including those discussed under the heading “Risk Factors” in G Medical’s Innovations Annual Report on Form 20-F for the year ended December 31, 2022, filed with the Securities and Exchange Commission (“SEC”) on May 16, 2023, and our other filings with the SEC, which are available on the SEC’s website, www.sec.gov. Except as otherwise required by law, G Medical Innovations undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Contact Details Rina Bar +972 54-724-0412 rinab@gmedinnovations.com Company Website https://gmedinnovations.com

January 05, 2024 03:17 AM Eastern Standard Time

Image

Align Surgical Practice Members Named to Influential Medical Advisory Roles

Align Surgical Associates

The California-based gender-affirming healthcare provider Align Surgical Associates Inc. (Align Surgical) announced today that two of its surgeons have been appointed to influential advisory roles by national medical societies. Align Surgical founder and CEO Thomas Satterwhite, M.D., has been named a contributing editor to Plastic and Reconstructive Surgery (PRS), the journal of the American Society of Plastic Surgeons (ASPS). Dr. Satterwhite was nominated for the role by the journal’s editorial leadership and confirmed this month by the full editorial board and the ASPS board of directors for a three-year term starting in January 2024. As a contributing editor, Dr. Satterwhite will serve as a peer reviewer on new research submissions and contribute his own writings, among other responsibilities. John Pang, M.D., F.A.C.S, will join the Guideline Development Panel of the Endocrine Society, the century-old organization at the forefront of hormone science and public health in the United States. This expert panel will spend two years developing and updating the Endocrine Society’s clinical practice guidelines on gender affirming care. During this time, this panel will meet, write and review evidence to rigorously develop and implement evidence-based practice-wide recommendations. “I am honored to join the editorial board of the leading journal in our field,” said Dr. Satterwhite, who is a board-certified plastic surgeon and Diplomate of the American Board of Plastic Surgery. “I congratulate Dr. Pang on his appointment to the Endocrine Society panel, a role that speaks to his considerable expertise. A key part of our vision for Align Surgical has been to make active research central to the practice. While this may be an unusual commitment for a private medical practice, I believe it is vital to achieve a deeper understanding of what is possible in the critical field of gender-affirming healthcare. We have a duty to pursue technical innovations and ultimately share our findings with our colleagues so that patient outcomes everywhere can improve. These national advisory opportunities are an extension of that commitment.” Thomas Satterwhite, M.D., is a board-certified reconstructive plastic surgeon and a Diplomate of the American Board of Plastic Surgery. Dr. Satterwhite completed his B.A. with honors, medical degree and plastic surgery residency at Stanford University in Palo Alto, CA. He specializes in all aspects of gender-affirming surgical procedures, including those for the face, body, chest and genital areas. Dr. Satterwhite is based at Align Surgical’s San Francisco office, serving patients from California and across the United States. John Pang, M.D., F.A.C.S., is a double board-certified plastic and reconstructive surgeon who specializes in complex genital, face and chest reconstruction, as well as aesthetic facial and body procedures. Dr. Pang received his medical degree from the John A. Burns School of Medicine at the University of Hawaii, Manoa. He completed a general surgery residency at Einstein Medical Center in Philadelphia, PA; a plastic and reconstructive surgery residency at the University of Pittsburgh in PA; and a transgender surgery/ plastic and reconstructive surgery fellowship at Mount Sinai Medical Center in New York, NY. Dr. Pang is based in San Francisco. * * * About Align Surgical Associates Align Surgical Associates was founded in 2018 with the mission of providing gender-affirming surgery to the transgender, non-binary and gender-diverse community with excellence, compassion and the belief that all people deserve to experience the freedom of living as their true selves. Align Surgical is one of the few interdisciplinary surgical practices in the United States that exclusively provides comprehensive gender-affirming care. Align Surgical’s surgeons in San Francisco and Los Angeles provide the full range of facial, body contouring, top and bottom surgeries and share a commitment to advancing innovation and research in their specialty fields. More information at alignsurgical.com. Media, please note: Visual assets, including photos and video, are available. To request an interview with experts from Align Surgical Associates, please contact Sean Dowdall at 415.286.7121 or Align@landispr.com. ### Contact Details Landis Communications Inc. Sean Dowdall +1 415-286-7121 Align@landispr.com Company Website https://www.alignsurgical.com/

January 04, 2024 06:01 AM Pacific Standard Time

Image

Healthcare

Defense Acquisition University (DAU) to Support NCMA Nexus 2024

UNOS Hires New Vice President of External Affairs

G Medical Innovations Announces First Half 2023 Financial Results and Provides Business Update

Human-augmented AI data marketplace Ta-Da debuts on strategic MultiversX incubator xLaunchpad

Beyond Diagnosis: Cardio Diagnostics' Actionable Clinical Intelligence Platform Provides Personalized Insights To Help Prevent Heart Attacks

5Scape VR Announces its Presale Going Live Today!

AmeriLife Names Gideon Moore Chief Legal Officer

Newsletter - How G Medical Innovations is transforming telehealth and mobile cardiac telemetry in 2024

Align Surgical Practice Members Named to Influential Medical Advisory Roles